Dendreon: 3 Areas You Must Watch

In the following video, Fool analysts David Williamson and Austin Smith discuss Dendreon (NASDAQOTH: DNDNQ  ) and some key areas for investors to watch.

For many investors, the health-care market can be an intimidating place. David says there are a few things Dendreon investors can focus on to avoid all the noise around the company.

Dendreon is currently testing its Provenge prostate cancer treatment against two other drugmakers' treatments for the disease. Showing a clinical benefit for using Provenge first would be huge, David says. It could hush skeptics and drive sales of the drug, which, at $93,000 a treatment, costs significantly more than the other drugs.

The company is also awaiting EU approval for its drug. Analysts are skeptical about that market, and for good reason, David says. Decisions on treatment are made by state-run health-care plans, which are typically much tougher negotiators. Dendreon might be forced to offer significant discounts.

That would put additional pressure on the company's already small margins, David says.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. Make sure you start 2013 with a bang and get the inside scoop on what Motley Fool superinvestor David Gardner will be buying this year. He's crushed the market in his Stock Advisor and Rule Breakers portfolios for years, and now you can take a personal tour of his flagship stock-picking service, Supernova. Just click here now for instant access.


Read/Post Comments (3) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 14, 2013, at 2:18 PM, pfan12000 wrote:

    David,

    please do a better job with the numbers. $93K is for a full course Provenge treatment from Dendreon versus (Zytiga at about 5,000 per month for 8-12 months) The upshot? Payers – and patients via co-pays—are being asked to fork out roughly $1600 more for monthly Xtandi than for Zytiga (based on the $7540 monthly wholesale acquisition cost announced by Medivation’s executives when Xtandi was approved August 31) for 6 additional days of survival. Google costs of Zytiga and Xtandi and the costs issue is not real so stop churning the false data talking points.

  • Report this Comment On January 15, 2013, at 12:10 PM, lebronz wrote:

    3 vids on dndn in 24 hours?

    Dave, yu da man!

    So ur saying when dndn announces a +EU CHMP opinion Monday the 21st, hedgies will short the positive event..?

    Well, no matter, dndn is a 3 year hold to the Jan, 2016 note due date and which also tracks CEO JJ and his staff/sales reps vesting of stock & options :-D

  • Report this Comment On January 15, 2013, at 1:15 PM, hsawaknow wrote:

    Leb,

    And you have at least 3 cryptic responses, to anything DNDN, in as many days.

    Your point and position is?

    Waiting....

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2193105, ~/Articles/ArticleHandler.aspx, 12/20/2014 8:42:34 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement